# Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

> **NCT01217775** · PHASE3 · UNKNOWN · sponsor: **Pherin Pharmaceuticals, Inc.** · enrollment: 1400 (estimated)

## Conditions studied

- Premenstrual Dysphoric Disorder

## Interventions

- **DRUG:** PH80
- **DRUG:** Placebo intranasal spray

## Key facts

- **NCT ID:** NCT01217775
- **Lead sponsor:** Pherin Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2017-03
- **Final completion:** 2017-07
- **Target enrollment:** 1400 (ESTIMATED)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217775, "Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01217775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*